Serotonin high sensitive ELISA Kit

Name: Serotonin high sensitive ELISA Kit
SKU: DEIA6182
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, urine, platelets, platelet-poor plasma, tissue homogenates, dialysates, and other samples

Species Reactivity

N/A

Detection Method

cELISA

Intended Use

Ultra-sensitive enzyme immunoassay for the quantitative determination of Serotonin. Flexible test system for various biological sample types and volumes.

Contents of Kit

1. Wash Buffer Concentrate 50×:
Content: Buffer with a non-ionic detergent and physiological pH
Volume: 1 × 20 ml/vial, purple cap
2. Enzyme Conjugate:
Content: Goat anti-rabbit immunoglobulins conjugated with peroxidase
Volume: 1 × 12 ml/vial, red cap
3. Substrate:
Content: Chromogenic substrate containing 3,3',5,5'-tetramethylbenzidine, substrate buffer and hydrogen peroxide
Volume: 1 × 12 ml/vial, black cap
4. Stop Solution:
Content: 0.25 M sulfuric acid
Volume: 1 × 12 ml/vial, grey cap
5. Serotonin Microtiter Strips:
Content: 1 × 96 wells (12 × 8) antigen precoated microwell plate in a resealable pouch with desiccant
6. Serotonin Antiserum:
Content: Rabbit anti-serotonin antibody, blue coloured
Volume: 1 × 3 ml/vial, blue cap
7. Acylation Buffer:
Content: TRIS buffer with non-mercury preservative
Volume: 1 × 4 ml/vial, yellow cap
8. Acylation Plate:
Content: 1 × 96 well plate, pre-coated with acylation reagent
9. Stabilizer:
Content: Stabilizing agent, 10% solution
Volume: 1 × 4 ml/vial, purple cap
10. Dilution Concentrate 20×:
Content: TRIS buffer with 1% stabilizing agent and a non-mercury preservative
Volume: 1 × 50 ml/vial, white cap
11. Standards and Controls

Conversion:
serotonin [ng/ml] × 5.67 = serotonin [nmol/l]
serotonin [pg/sample volume] × 5.67 = serotonin [pmol/sample volume]
Content: TRIS buffer with non-mercury preservative, spiked with defined quantity of serotonin
Note: Standards and controls have to be diluted 1+1000 prior to use (please see Reagent Preparation for further information).The shown concentrations apply to diluted standards and controls (1+1000) when 100 μl of undiluted sample isused. Please refer to Calculation of results for the use of a correction factor in case of using diluted samples and/or less samplevolume.
Note: Allow all reagents and samples to reach room temperature and mix thoroughly by gentle inversion before use. Number the microwell plates (Microtiter Strips which are removed from the frame for usage should be marked accordingly to avoid any mix-up). Duplicate determinations are recommended.
The binding of the antisera and of the enzyme conjugate and the activity of the enzyme are temperature dependent. The higher the temperature, the higher the absorption values will be. Varying incubation times will have similar influences on the absorbance. The optimal temperature during the enzyme immunoassay is between 20 – 25 °C.

Storage

Store kit and reagents at 2 – 8 °C until expiration date. Do not use kit and components beyond the expiry date indicated on the kit labels. Once opened, the reagents are stable for 2 months when stored at 2 – 8 °C. Once the resealable pouch of the ELISA plate has been opened, care should be taken to close it tightly again including the desiccant.

Sensitivity

0.005 ng/ml × Correction factor

Standard Curve

The standard curve, which can be used to determine the concentration of the unknown samples, is obtained by plotting the absorbance readings (calculate the mean absorbance) of the standards (linear, y-axis) against the corresponding standard concentrations (logarithmic, x-axis). Use non-linear regression for curve fitting (e. g. 4-parameter, marquardt).
This assay is a competitive assay. This means: the OD-values are decreasing with increasing concentrations of the analyte. OD-values found below the standard curve correspond to high concentrations of the analyte in the sample and have to be reported as being positive.
The concentrations of the samples taken from the standard curve have to be multiplied by a correction factor:

Three different examples are shown to illustrate the calculation of possible correction factors:
Example 1:
10 μl of the undiluted sample are acylated and the concentration taken from the standard curve is 0.02 ng/ml serotonin.
Correction factor = 100/10 = 10
Final concentration of the sample = 0.02 ng/ml × 10 = 0.2 ng/ml serotonin
Example 2:
100 μl of the 1:100 prediluted sample are acylated and the concentration taken from the standard curve is 0.02 ng/ml serotonin.
Correction factor = 100
Final concentration of the sample = 0.02 ng/ml × 100 = 2.0 ng/ml serotonin
Example 3:
10 μl of the 1:100 prediluted sample are acylated and the concentration taken from the standard curve is 0.02 ng/ml serotonin.
Correction factor = 100 × (100/10) = 1000
Final concentration of the sample = 0.02 ng/ml × 1000 = 20 ng/ml serotonin
Conversion
Serotonin [pg/ml] × 5.67 = Serotonin [pmol/l]
Serotonin [pg/sample volume] × 5.67 = Serotonin [pmol/sample volume]
Quality control
The confidence limits of the kit controls are indicated on the CoA.

Citations

Have you cited DEIA6182 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A Review of Molecular Imaging of Glutamate Receptors

MOLECULES

Authors: Kim, Jong-Hoon; Marton, Janos; Ametamey, Simon Mensah; Cumming, Paul

Abstract

Molecular imaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) is a well-established and important in vivo technique to evaluate fundamental biological processes and unravel the role of neurotransmitter receptors in various neuropsychiatric disorders. Specific ligands are available for PET/SPECT studies of dopamine, serotonin, and opiate receptors, but corresponding development of radiotracers for receptors of glutamate, the main excitatory neurotransmitter in mammalian brain, has lagged behind. This state of affairs has persisted despite the central importance of glutamate neurotransmission in brain physiology and in disorders such as stroke, epilepsy, schizophrenia, and neurodegenerative diseases. Recent years have seen extensive efforts to develop useful ligands for molecular imaging of subtypes of the ionotropic (N-methyl-D-aspartate (NMDA), kainate, and AMPA/quisqualate receptors) and metabotropic glutamate receptors (types I, II, and III mGluRs). We now review the state of development of radioligands for glutamate receptor imaging, placing main emphasis on the suitability of available ligands for reliable in vivo applications. We give a brief account of the radiosynthetic approach for selected molecules. In general, with the exception of ligands for the GluN2B subunit of NMDA receptors, there has been little success in developing radiotracers for imaging ionotropic glutamate receptors; failure of ligands for the PCP/MK801 binding site in vivo doubtless relates their dependence on the open, unblocked state of the ion channel. Many AMPA and kainite receptor ligands with good binding properties in vitro have failed to give measurable specific binding in the living brain. This may reflect the challenge of developing brain-penetrating ligands for amino acid receptors, compounded by conformational differences in vivo. The situation is better with respect to mGluR imaging, particularly for the mGluR5 subtype. Several successful PET ligands serve for investigations of mGluRs in conditions such as schizophrenia, depression, substance abuse and aging. Considering the centrality and diversity of glutamatergic signaling in brain function, we have relatively few selective and sensitive tools for molecular imaging of ionotropic and metabotropic glutamate receptors. Further radiopharmaceutical research targeting specific subtypes and subunits of the glutamate receptors may yet open up new investigational vistas with broad applications in basic and clinical research.

Postoperative Serotonin Syndrome Following Methylene Blue Administration for Vasoplegia After Cardiac Surgery: A Case Report and Review of the Literature

SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA

Authors: Basta, Mafdy N.

Abstract

Serotonin syndrome is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system. The increasing incidence of this condition is thought to parallel the increasing use of serotonergic agents in medical practice. The selective serotonin reuptake inhibitors are perhaps the most commonly implicated group of medications associated with serotonin syndrome. This case report describes the occurrence of postoperative serotonin syndrome in a patient on long-term sertraline who underwent coronary artery bypass graft and was treated with methylene blue for perioperative vasoplegia. It delineates the various clinical features commonly encountered and illustrates the recommended management modalities, including prevention, for this potentially lethal medical emergency. With prompt diagnosis and expeditious treatment, the patient has had full recovery.